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Interferon-α (IFNα) has one of the longest histories of use amongst cytokines in clinical
oncology and has been applied for the treatment of many types of cancers. Due to
its immune-activating properties, IFNα is also an attractive candidate for combinatory
anti-cancer therapies. Despite its extensive use in animal tumor models as well as in
several clinical trials, the different mechanisms underlying patient responses and affecting
desirable clinical benefits are still under investigation. Here we show that in addition
to its immune-activating properties, IFNα induces the expression of a key negative
regulator, immunosuppressive PD-L1molecule, in the majority of the specific immune cell
populations, particularly in the dendritic cells (DC). DC can modulate immune responses
by a variety of mechanisms, including expression of T-cell regulatory molecules and
cytokines. Our results showed that treatment of DC with IFNα-2b led to pronounced
up-regulation of surface expression of PD-L1 molecules, increased IL-6 and decreased
IL-12 production. Moreover, we present evidence that IFNα-treated DC exhibited a
reduced capacity to stimulate interferon-γ production in T cells compared to control DC.
This T-cell response after treatment of DC with IFNα was recovered by a pre-treatment
with an anti-PD-L1 blocking antibody. Further analyses revealed that IFNα regulated
PD-L1 expression through the STAT3 and p38 signaling pathways, since blocking of
STAT3 and p38 activation with specific inhibitors prevented PD-L1 up-regulation. Our
findings underline the important roles of p38 and STAT3 in the regulation of PD-L1
expression and prove that IFNα induces STAT3/p38-mediated expression of PD-L1 and
thereby a reduced stimulatory ability of DC. The augmentation of PD-L1 expression
in immune cells through IFNα treatment should be considered by use of IFNα in an
anti-cancer therapy.
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INTRODUCTION
The cytokine interferon-α (IFNα) has been used for a long
time for treatment of many types of cancers, such as renal cell
carcinoma, malignant melanoma or chronic myeloid leukemia
(1, 2). However, the molecular mechanisms affecting patient
responses and clinical outcome of IFNα therapy are still under
investigation. IFNα is a member of the type I interferon family
and is produced by various cell types, including monocytes,
macrophages, lymphoblastoid cells, fibroblasts and plasmacytoid
dendritic cells (3). Initially utilized as an anti-viral agent and
meant for use in tumors where a viral origin was suspected, IFNα
initiated a variety of biological activities that warranted further
investigation. Indeed, this cytokine manifests direct suppressive
effects on tumor cell growth in vitro and in vivo (4) and enhances
tumor recognition by the increase in MHC-1 expression.
Additionally, radio- and chemo-sensitizing capacities, as well
as anti-angiogenic properties, have been described for IFNα
(5, 6). Furthermore, Essers and colleagues have showed that the
cytokine activated dormant hematopoietic stem cells in vivo (7).
We have confirmed this phenomenon in pancreatic cancer, where
we found that IFNα exhibited the ability to activate stem cell
markers (8). Meanwhile, the immunostimulatory characteristics
of IFNα have gained special attention since they can affect the
differentiation of DC, survival of T cells, generation of CD8+
memory cells, macrophage activities and activation of natural
killer (NK) cells (9). A lot of tumor entities, like pancreatic
cancer, are characterized by reduced immunological defense (10,
11). A combination of chemotherapy with immune stimulation
could improve therapy efficacy and provide an optimal cancer
treatment (12). Armed with its attributes, IFNα could be an
attractive candidate for combinatory therapies. Indeed, IFNα-
2b (trade name Intron-A), a well-known IFN-based therapeutic
(13) that is approved for the treatment of various infectious
diseases as well as for many types of cancer including leukemia,
lymphoma, multiple myeloma and malignant melanoma, is also
actively used in multiple clinical trials (http://www.druglib.com/
druginfo/intron-a/trials/).
However, it has become increasingly clear in the last
few years that certain cytokines originally described as
immunostimulatory and pro-inflammatory, could also up-
regulate immunosuppressive molecules. Such molecules
are key elements of immune inhibitory pathways, so-called
immunological checkpoints, which are crucial for maintaining
self-tolerance and modulating the strength of immune responses.
The most prominent of them is the PD-L1 (Programmed
death-ligand 1, CD274, B7-H1)–PD-1 axis. PD-L1 is a type 1
transmembrane glycoprotein and one of two ligands for the
CD28 homolog programmed death-1 receptor (PD-1) (14). The
protein expression of PD-L1 can be found on immune cells as
well as on non-immune endothelial and epithelial cells and can
be up-regulated by different agents, such as cytokines and TLR
(toll-like receptor) ligands (15–19). The PD-L1 molecule plays
an important role in controlling immune reactions by inhibiting
T-cell response and by influencing several other cell types. It
is implicated in a number of human and mouse disorders as
well as in transplant rejection and pregnancy complications
(14, 20, 21). Additionally, it is responsible for the chronification
of viral and bacterial infections (22). The expression of this
molecule contributes as well to tumor immune evasion and
correlates with a poor prognosis for the cancer patient (23–26).
This makes PD-L1 and its regulation an important target for
on-going investigations that aim to develop new anti-cancer
treatment strategies. Interferons have been shown to be able to
regulate PD-L1 expression not only on tumor (25) but as well on
several non-tumor cell types: IFNγ increases PD-L1 in dermal
fibroblasts (15), hepatic stellate cells (27) and DC (28, 29);
the up-regulation of PD-L1 in DC by IFNβ contributes to
immunomodulatory effects of this cytokine in multiple sclerosis
and in lipopolysaccharide-induced immune paralysis (30, 31)
and the expression of PD-L1 in hepatocytes and in myeloid cells
in vitro can be augmented by IFNα (29, 32).
The stimulation of PD-L1 expression by IFNα could
make a substantial negative contribution in patient responses
and clinical outcomes of IFNα therapy through increased
immunosuppression. Therefore, in this work we investigated
the mechanisms of regulation of PD-L1 expression in specific
immune cell populations by IFNα.
MATERIALS AND METHODS
Antibodies and Reagents
Anti-mouse monoclonal antibodies directly conjugated to
fluorophores against the following targets of interest were used:
F4/80, PD-L1, and Foxp3 (eBioscience, Germany); CD4, CD3e,
CD44, CD8a, CD62L, CD45R, CD11b, CD11c, Gr-1, NK1.1,
CD25, Ly6C, and PD-1 (BD Bioscience, Germany). Fc receptor
binding inhibitor (anti-mouse CD16/CD32) was purchased from
eBioscience (Germany). Anti-human antibodies included anti-
PD-L1-PE and purified anti-PD-L1 blocking antibody (both
from eBioscience, Germany). For western blot, anti-phospho-
ERK42/44, anti-phospho-p38 and anti-phospho STAT3 along
with their reference antibodies, anti-ERK42/44, anti-p38, and
anti-STAT3 antibody (all from Cell Signaling Technology,
USA), were used. Signal transduction inhibitors: UO126
(MEK1/2 inhibitor, Cell Signaling Technology, USA), SB203580
(p38 MAPK inhibitor, Cell Signaling Technology, USA),
LY294002 (PI3K inhibitor), CAS457081-03-7 (Jak inhibitor
1, Calbiochem, Germany) and Cucurbitacin/JSI-124 (STAT3
inhibitor, Calbiochem, Germany). Cytokines used included IL-4,
GM-CSF, TNF-α, IL-6, IL-1β, PGE2 (Promokine, Immunotools,
Strathmann, Germany) and IFNα (R&D; IntronA, Interferon
alfa-2b, Schering-Plough; Germany).
Mice
C57BL/6 mice were purchased from Charles River (Germany)
and bred and maintained under specific pathogen-free
conditions in the animal facility of the University of Heidelberg
(IBF, Heidelberg). Animal experiments were carried out
after approval by the Karlsruhe regional government council
(Regierungspraesidium Karlsruhe, 35-9185.81/G-184/11). The
following experimental groups have been used: (1) control group
(vehicle injection) and (2) treatment group (injection of IFNα).
Healthy mice were intraperitoneally injected three times within 1
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week with 50 µl of IFNα (2× 105 U/ml) or an equivalent volume
of vehicle control with subsequent examination of the mouse
splenocytes by flow cytometry.
Generation of Human DC
Buffy coats for research purposes were provided by blood donor
service BSD Mannheim. Human peripheral blood myeloid DC
(mDC) were isolated from freshly-prepared PBMCs from whole
blood usingMACS isolation kit (Miltenyi, Germany) as described
elsewhere (19), according to the manufacturer’s protocol. Human
monocyte-derived DC (MoDC) were generated as described
previously (19). Briefly, PBMCs were prepared from whole blood
by Biocoll gradient centrifugation (Biochrom AG, Germany).
Isolated plastic-adherent monocytes were cultured in X-vivo
15 medium (Bio-Whittaker, Belgium) supplemented with 1.5%
human plasma in the presence of the cytokines GM-CSF and IL-4
for 5–6 days.
Cytokine Treatment
The following cytokine concentrations were used for the
treatment of DC: standard cytokine cocktail for maturation
(10 ng/ml TNF-α, 1,000U/ml IL-6, 10 ng/ml IL-1β, 1µg/ml PGE)
and 500–6,000U IFNα for generating the dose-dependent curve.
For other experiments, DC were treated with 1,000 U/ml IFNα
for 24 h and subjected to FACS analysis, western blot or DC-T-cell
co-cultures.
DC-T-Cell Co-cultures
DC and T-cells were co-cultured as described previously (19).
Generated or freshly isolated DC were pretreated with 1,000
U/ml IFNα for 24 h and then washed twice with medium. CD4+
cells were isolated from freshly-prepared PBMCs using MACS
beads (Miltenyi, Germany). CD4+ cells and DC were cultured
together in 96-well round-bottom plates for 5 days, after which
the production of cytokines in supernatants was determined in
triplicates using Luminex assay.
Immunocytochemistry
Immunocytochemistry was performed as described elsewhere
(8). Briefly, cells were immobilized on microscope slides using
a cytocentrifuge, fixed with 3.7% formaldehyde, pre-absorbed
and incubated with anti-PD-L1 or control antibody. After
incubation with secondary biotin-coupled antibodies followed
by streptavidin–phosphatase complexes, PD-L1 was detected
through the formation of a colored reaction product from the
hydrolysis of substrate by alkaline phosphatase. Hematoxylin was
used for counterstaining nuclei.
Western Blot Analysis
DC treated with 1,000 U/ml IFNα for the indicated periods
of time were harvested, lysed in 2× sample buffer (100mM
Tris, pH 6.8, 4% SDS, 16% glycerol, 0.57M β-mercaptoethanol,
0.01% bromophenol blue) and heated to 95◦C for 5min. SDS-
PAGE was carried out after loading the proteins onto a 10%
polyacrylamide gel. After transfer to PVDF membranes, the
blots were sequentially blocked for 2 h using 5% milk in TBST
solution (10mM Tris, pH 8.0, 150mM NaCl, 0.1% Tween-20),
incubated overnight with primary antibodies in TBST containing
5% BSA, washed three times in TBST and incubated with HRP-
conjugated secondary antibodies. Subsequently, the proteins of
interest were detected by chemiluminescence produced by HRP-
catalyzed oxidation of ECL substrate (Lumigen TMA6, UK).
Flow Cytometry Analysis
Cells were collected, washed and incubated for 15min at 4◦C
in FACS buffer containing antibodies directly conjugated to
fluorophores. The fluorescence was evaluated using a FACSCanto
II flow cytometer (BD Biosciences, Germany) and data were
analyzed with Diva and FlowJo Software (BD Biosciences,
Germany). All isotype controls had fluorescence values that
remained below a threshold of 1 × 103. For analysis of
murine leukocytes, a freshly-isolated splenocyte cell suspension
was prepared as described previously (33), resuspended in the
stain buffer (PBS supplemented with 1% mouse serum and
1mM EDTA), counted and adjusted to a concentration of 4 ×
107 cells/mL. Cells were blocked with anti-mouse CD16/CD32
antibodies at 4◦C in the dark for 10min and then incubated
with stain buffer containing various combinations of previously
titrated monoclonal antibodies at 4◦C in the dark for 15min.
After two washing steps with the stain buffer, the cells were
used for flow cytometry analysis. For intracellular staining,
Foxp3 buffer set was used according to the manufacturer’s
instruction. All the gates were set according to the corresponding
fluorescence minus one (FMO) controls. For the gating strategy
see Figure S1 and the manuscript from Fritz et al. (33).
Luminex Assay
Analyses of human cytokines IL-6, IL-12(p40), IFNγ, IL-
1b,−4,−5,−10,−12(p70), and−17 as well as TNF-α in culture
supernatants were performed as described elsewhere (34) using
a MILLIPLEX R© MAP Kit (Millipore GmbH, Schwalbach/TS,
Germany) according to the manufacturer’s instructions. The
measurements were performed in triplicates using a Luminex R©
100/200 System.
Statistical Analysis
The data were analyzed with unpaired Student’s t-test or one-way
ANOVA using GraphPad PRISM 5.0. Values with p < 0.05 were
considered significant. Quantitative data are expressed as mean
± SEM.
RESULTS
Expression of PD-L1 and PD-1 on Various
Populations of Murine Immune Cells
Our first aim was to determine the distribution of PD-L1 and
PD-1 expression on extracellular surfaces of different specific
immune cell populations. For this purpose, splenocytes from
BL6 mice were subjected to a deep FACS analyses (Figure S1) to
obtain the results summarized in Table 1. Expression of PD-L1
was found on all immune cells tested with higher percentages
of PD-L1+ cells (more than 80%) in conventional myeloid
DC (cDC, CD11chighCD11b+), macrophage (CD11b+Gr-
1−F4/80+), naïve CD8 cell (CD62L+CD44−), effector memory
(em) CD4 cell (CD62L−CD44+) and regulatory T cell (Treg,
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TABLE 1 | Distribution of PD-1 and PD-L1 expression on immune cell subpopulations.
PD-1 PD-L1
Cell frequency, % MFI Cell frequency, % MFI
CD3−NK1.1+CD4− 4.02 (±1.35) 992.6 (±407.4) n.d. (not detected) n.d.
CD3+NK1.1+CD4+ 22.55 (±12.98) 2,308 (±298.2) n.d. n.d.
CD11chighCD11b+ n.d. n.d. 91.73 (±4.44) 22,500 (±25.5)
CD11cintCD45R+ n.d. n.d. 58.3 (±14.79) 5,913 (±233.3)
CD11b+Gr-1−F4/80+ n.d. n.d. 82.3 (±0.63) 9,223 (±70)
CD11b+Gr-1+ n.d. n.d. 21.58 (±11.69) 7,669 (±2,250)
CD11b+Gr-1highLy-6Cint n.d. n.d. 15.27 (±6.99) 4,040 (±2,329)
CD11b+Gr-1intLy-6Chigh n.d. n.d. 44 (±10.52) 6,772 (±1,539)
CD8+CD3+ 11.16 (±6.72) 1,103 (±437.7) 81 (±26.73) 683 (±49.5)
CD62L−CD44+CD8+ n.d. n.d. 1.34 (±0.26) 993 (±162.6)
CD62L+CD44+CD8+ n.d. n.d. 64.65 (±0.26) 876 (±86.3)
CD62L+CD44−CD8+ n.d. n.d. 83.35 (±0.26) 554 (±22.6)
CD62L−CD44−CD8+ n.d. n.d. 1.47 (±0.26) 671 (±166.9)
CD4+CD3+ 14. 54 (±4.88) 1,468 (±429.3) 57.87 (±27.65) 1,568 (±1,686)
CD62L−CD44+CD4+ n.d. n.d. 85.8 (±6.79) 1,490 (±16.3)
CD62L+CD44+CD4+ n.d. n.d. 44.05 (±7.99) 1,688 (±359.9)
CD62L+CD44−CD4+ n.d. n.d. 48.75 (±40.94) 801 (±14.1)
CD62L−CD44−CD4+ n.d. n.d. 41.9 (±40.94) 1,494 (±304.1)
CD25dimFoxP3+CD4+ 39.18 (±9.83) 2,226 (±343.5) 54.3 (±40.94) 3,156 (±2,771)
CD25+FoxP3+CD4+ 24.15 (±6.65) 2,213 (±355.8) 84.45 (±9.12) 3,223 (±2,785)
CD25+FoxP3−CD4+ 18.68 (±7.59) 1,654 (±266.4) 4.2 (±5.06) 2,632 (±2,722)
CD25−FoxP3−CD4+ 77.07 (±2.74) 1,400 (±187.3) 70.25 (±0.64) 2,583 (±2,786)
CD4+CD25+FoxP3+) populations. The lowest percentages of
PD-L1+ cells (lower than 5% positive cells) were found in em cells
(CD62L−CD44+) and naïve CD8+ cells as well as in activated
conventional (con) T cells (Tcon, CD4+CD25+FoxP3−).
Expression of PD-1 was also found on all lymphoid cell
populations analyzed (Table 1). Thus, PD-L1 and its receptor are
commonly present on various murine immune cells.
IFNα Up-Regulates ex vivo and in vivo
Expression of PD-L1 on Mouse Leukocytes
In the next step, isolated splenocytes were treated for 24 h with
1,000 U/ml IFNα and PD-L1 expression on splenocytes was
detected with flow cytometry. IFNα treatment led to increased
percentages of cells expressing PD-L1 in plasmacytoid DC
(pDC), macrophage and CD11b+Gr−1+ cell populations, but
not in cDC in the myeloid leukocyte population (Figure 1).
The reason is that cDC are already PD-L1 positive to a high
percentage (Table 1). However, the level of PD-L1 expression
(measured in MFI, mean fluorescent intensity) was positively
affected in both DC subpopulations of CD11b+ cell (Figure 1).
In the lymphocyte population, IFNα treatment increased a
number of PD-L1+ cells and up-regulated the expression of
PD-L1 in both CD4+ and CD8+ cells (Figure 2). In specific
subpopulations of CD4+ cells, the percentage of cells expressing
PD-L1+ was increased in eff, em and cm (CD62L+CD44+)
cells and the level of PD-L1 expression was higher after IFNα
treatment in all subpopulations (Figure 2). Interferon-α was
observed to exert a similar effect in Treg (Figure 2). For the
gated CD8+ cells, an increased number of PD-L1+ cells was
found in eff, em and cm populations (Figure 2). The level of
PD-L1 expression measured in MFI was higher after treatment
with IFNα in all subpopulations except eff CD8+ cells (Figure 2).
Thus, IFNα is capable of up-regulating PD-L1 expression in
different murine immune cells.
Since the highest initial percentage of PD-L1+ cells and up-
regulation of PD-L1 after IFNα treatment was observed in DC
in ex vivo splenocytes cultures, the in vivo regulation of PD-L1
expression by IFNα was examined and we verified a similar up-
regulation in mouse DC (Figure 3) as well as in other myeloid
cells (data not shown).
IFNα Up-Regulates the Expression of
PD-L1, Increases the Production of IL-6
and Decreases the Production of IL-12 by
Human DC
To increase the clinical relevance of our study, we extended
our research to investigate PD-L1 regulation in human DC
facilitated through the use of IFN-based therapeutic IFNα-2b
(Intron A). Myeloid DC were isolated from buffy coats of healthy
human subjects and cultivated with different concentrations
of IFNα as indicated in Figure 4. The treatment induced
dose-dependent up-regulation of PD-L1 expression in the cells
(Figure 4A). Similarly, PD-L1 expression was up-regulated in
MoDC obtained from buffy coats of human healthy donors
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FIGURE 1 | IFNα up-regulates PD-L1 expression on different myeloid immune cell populations ex vivo. FACS analysis of PD-L1 expression on the surface of different
myeloid immune cells from splenocytes of healthy mice. Splenocytes were isolated, treated for 24 h with 1,000 U/ml IFNα and investigated by flow cytometry. The
results are presented as interleaved bars (A,B), as box and whiskers plots (C,E) or column bar graphs (D,F) and statistically analyzed using two-way ANOVA (A,B) or
unpaired T-tests (C–F), n = 4, **p < 0.01, and ***p < 0.001.
(Figure 4B). Remarkably, an increased PD-L1 expression was
still induced when mDC and MoDC were pulsed with IFNα
after incubation with a classical maturation cytokine cocktail
(Figure S2). Therefore, IFNα can specifically induce PD-L1
overexpression in human DC.
Produced cytokines are important indicators of DC
functionality. After the treatment of DC with IFNα, 10 human
cytokines were measured in cell culture supernatants using the
Luminex platform. We found an increased concentration of IL-6
and a decreased concentration of IL-12(p40) and IL-12(p70) in
the supernatants (Figure 4C) after IFNα treatment. However,
the production of IFNγ, IL-1β,−4,−5,−10, and−17 as well as
TNF-α was not affected (data not shown).
Blocking PD-L1 Leads to Recovery of IFNγ
Production by CD4+ Lymphocytes
Cultivated With IFNα-Treated mDC
The expression of PD-L1 on DC negatively modulates their
ability to activate CD4+ lymphocytes and subsequent IFNγ
production (19). Based on our findings above indicating that
IFNα treatment affects IFNγ production by co-cultured CD4+
lymphocytes but not DC, we aimed to investigate whether
the blocking of PD-L1 protein with antibodies [anti (α)-
PD-L1] could influence IFNγ production in our co-culture
experiments. In order to achieve the above aim, we co-cultivated
CD4+ cells with mDC pretreated with IFNα, anti-PD-L1 or
both IFNα and anti-PD-L1. As expected, the co-cultivation of
CD4+ cells with untreated mDC led to an increase in the
amount of IFNγ in the supernatants and addition of anti-PD-
L1 antibody further improved the cytokine release (Figure 5).
Treatment of CD4+ cells with anti-PD-L1 but without mDC
did not induce IFNγ production. Pre-incubation of mDC with
IFNα resulted in a decrease in the amount of IFNγ in the
supernatants of co-cultivated CD4+ cells (Figure 5), which
could be explained by the up-regulation of PD-L1 expression
on mDC. Indeed, blocking of IFNα-induced PD-L1 on DC
led to higher IFNγ production from co-cultivated CD4+ cells
compared to the co-cultures containing IFNα-DC without an
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FIGURE 2 | IFNα up-regulates PD-L1 expression on different T-cell populations ex vivo. FACS analysis of PD-L1 expression on the surface of different lymphoid
immune cells from spleens of healthy mice. Splenocytes were isolated, treated for 24 h with 1,000 U/ml IFNα and investigated by flow cytometry. The results are
presented as interleaved bars (A) or as box and whiskers plot or column bar graph (B) and statistically analyzed using two-way ANOVA or unpaired T-tests, n = 4,
*p < 0.05, **p < 0.01, and ***p < 0.001.
αPD-L1 antibody blockade. The restoration of IFNγ production,
resulted in the same amount of the cytokine released into
the supernatant as in the samples that were co-cultivated with
mDC without any pre-treatment (Figure 5). Thus, blocking
PD-L1 leads to the recovery of IFNγ production by CD4+
lymphocytes activated with IFNα-treated mDC. The same results
were observed when MoDC were used instead of mDC (data not
shown).
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FIGURE 3 | IFNα up-regulates PD-L1 expression on DC in vivo. FACS analysis of PD-L1 expression on the surface of DC from spleens of healthy mice with or without
treatment with IFNα. Splenocytes were isolated and examined using flow cytometry. The results are presented as percent of positive cells in a column bar graph and
statistically analyzed using unpaired T-test, n = 10, ***p < 0.001. A representative FACS histogram (red-control, blue-IFNα) is shown.
Inhibitors of STAT3, p38 and Jak
Down-Regulate the Expression of PD-L1
Induced by IFNα, Whilst PI3K or ERK
Inhibitors Do Not Exert This Effect
Finally, we wanted to identify the molecular mechanisms
by which IFNα up-regulates PD-L1 expression. We treated
human mDC obtained from buffy coats with inhibitors of
different signaling proteins as indicated in Figure 6. We found
that IFNα-induced PD-L1 expression was down-regulated by
inhibitors of p38, Jak and STAT3 but not by inhibitors of
PI3K or ERK (Figure 6A). However, combinations of two
different inhibitors did not show additive inhibitory effects
(Figure 6B). In line with these observations, IFNα could increase
the phosphorylation of p38 and STAT3 as shown by western
blot (Figure 6C). In addition, we did not observe any effect
on PD-L1 expression when NF-kB or STAT1/STAT5 were
blocked with specific inhibitors (data not shown). Therefore,
we concluded that signaling cascades including Jak/STAT3
and p38 could be involved in the regulation of PD-L1
expression.
DISCUSSION
In this study, we showed for the first time that PD-L1 molecule
was expressed and could be up-regulated in the majority of
specific immune cell populations by IFNα.
Programmed death-ligand 1, expressed on different
immune cells, such as MDSC (35, 36), T cells (37), DC
(19, 38), macrophages (39), pDC (40), is able to cause
immunosuppression. Taking into account the ubiquitous
expression of PD-L1 receptor (PD-1) on non-myeloid specific
immune cells (CD8, CD4 and Treg), our results indicate that
immunotherapy with IFNα could lead to an undesirable side
effect of general immunosuppression and consequently to
increased tumor immune evasion or chronification of infection.
Our data could also explain the insufficiency of IFNα therapy
observed in several models, despite its promising in vitro
and immunomonitoring results (41–44). We propose that the
combination of IFNα with checkpoint inhibitors like PD-L1
blocking antibody, could repress this immunosuppressive path
and improve the efficiency of IFNα therapy by uncoiling the
immune costimulatory potential of IFNα. While the majority
of the DC are already positive for PD-L1, the intensity of this
expression could be strongly up-regulated in our study by
IFNα in vivo, ex vivo, and in vitro. DC play a crucial role in
the control of adaptive tolerance and immunity and modulate
immune responses by multiple mechanisms, including the
production of cytokines and expression of T-cell regulatory
molecules. Their final stimulatory capacity depends on the
balance between stimulatory and suppressive pathways,
whereby PD-L1 provides one of the most decisive suppressive
signals and leads to unfavorable outcomes due to decreased
anti-tumor immunity. This becomes particularly evident by
documentation of reduced DC functions in several types
of cancer and chronic infections (45–53). In cases utilizing
vaccination as immunotherapeutic approaches against tumor
and viral antigens, it is important that the produced DC
display their full activation capacity (54, 55). Therefore, many
therapies aim to activate DC to increase their stimulatory
potential. IFNα was suggested as one of potential candidates
for non-specific immune stimulation or as a replacement
of IL-4 in the process of Mo-DC production (56–59). In
accordance with our data, the MoDC produced from the
monocytes treated with GM-CSF and IFNα (IFNα/GM-CSF
MoDC) had a higher expression of PD-L1 molecules compared
to those treated with IL-4/GM-CSF (60). In this case, the
therapeutic efficacy of DC produced or activated with IFNα
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FIGURE 4 | IFNα up-regulates PD-L1 expression on human dendritic cells. (A) FACS analysis of PD-L1 expression on the surface of mDC. Myeloid DC were isolated,
treated for 24 h with IFNα and analyzed with flow cytometry. The results are presented as column mean, error bars and mean connected and statistically analyzed
using ordinary one-way ANOVA with the Tukey’s multiple comparisons post-test, n = 2, *p < 0.05 and **p < 0.01. (B) FACS analysis and Immunocytochemistry (ICH)
of PD-L1 expression on the surface of MoDC. MoDC were treated for 24 h with 1,000 U/ml IFNα and analyzed with flow cytometry. Alternatively, cytospin slides were
produced and ICH was performed using an anti-PD-L1 primary antibody followed by a biotinylated secondary antibody. FACS histograms (red-control, blue-IFNα) and
ICH pictures are representative for independent experiments. (C) Cytokines in the supernatant of the IFNα-treated DC analyzed with Luminex assays. The results are
presented as column bar graphs and statistically analyzed using unpaired T-test, n = 2.
could be improved by the simultaneous reduction of PD-L1
expression.
The IFNα-treated DC demonstrated increased IL-6 and
decreased IL-12 production. This is in line with the observation
that TLR-antigen presenting cells, which express a high
amount of PD-L1 and fail to induce T-cell proliferation, also
exhibited increased IL-6 production (61). IFNα can inhibit IL-12
production in mouse splenocytes (62) and IL-12p40 production
in human MoDC (57, 63). However, IL-6 has been shown
to down-regulate IL-12 production by human MoDC (64). In
our model, the cause of decreased IL-12 production, whether
directly through IFNα treatment or partially caused as an
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FIGURE 5 | PD-L1 controls IFNγ release from CD4T cells stimulated by DC.
Allogeneic CD4 cells were isolated and cocultured with DC in the presence or
the absence of anti-PD-L1 blocking antibody or vehicle control. The level of
IFNγ in supernatants was determined by Luminex assay. The results are
presented as column bar graphs and statistically analyzed using ordinary
one-way ANOVA with the Tukey’s multiple comparisons post-test, n = 3–6, *p
< 0.05, ***p < 0.001, and ****p < 0.0001.
effect of IL-6, remains to be clarified. Moreover, we reported
previously that IL-6 is able to induce PD-L1 in DC per se (18),
thus PD-L1 expression could be boosted additionally by this
loop.
In accordance with the findings of other researchers, we
have shown previously that specific up-regulation of PD-L1
regulatory molecules on DC surfaces affect the capacity of DC
to induce T-cell cytokine production (19, 30). In line with
these previous results, we found that IFNα-treated DC strongly
down-regulated IFNγ production by T cells. However, IL-12,
produced by antigen-presenting cells including DC, can also
control the production of IFNγ by T cells (65) and this is
as well-evident when IFNγ release by co-cultured CD4T cells
decreased in response to diminished IL-12p70 production by IL-
6 treated DC (64). In our study, the decrease in IL-12 production
might not have an important role in stimulating IFNγ release
in the co-cultures, since blocking PD-L1 on IFNα-treated DC
could almost completely restore IFNγ release. Thus, in our
experimental settings, the inhibitory ability of IFNα is directly
linked to increased PD-L1 expression on DC. Given that IFNγ
induces the expression of PD-L1 in DC (28, 29), repression of
IFNγ production by T cells by IFNα could negatively regulate de
novo expression of PD-L1 on the surface of DC during immune
response in vivo.
The decisive role held by PD-L1 molecule in controlling
immune response and anti-tumor immunity urges the
investigation of signaling events controlling its up-regulation.
Elucidation of the PD-L1 regulation on DC is an emerging
field, as these cells govern the decision between tolerance and
immunity. By canonical way, ligand engagement of the IFNα
receptor (IFNAR, composed of the IFNAR1 and IFNAR2
subunits) activates Jak1 and tyrosine kinase 2 (TYK2) and can
result in the recruitment of STATs as well as MAPKs, PI3K,
Akt, NF-kB and PRMT1 (66). There are three predominant
STAT complexes that might be formed in response to IFNs:
(i) The interferon-stimulated gene factor 3 (ISGF3) complex
[STAT1/STAT2 and IFN-regulatory factor 9 (IRF9)], which
binds to IFN-stimulated response element (ISRE) sequences
and activate antiviral genes, (ii) STAT1 homodimers, which
bind to gamma-activated sequences (GASs) and initiate pro-
inflammatory genes, and (iii) STAT3 homodimers which
indirectly suppress pro-inflammatory gene expression. Our
experiments revealed that IFNα regulates PD-L1 expression
in a Jak-, STAT3-, and p38-dependent manner. Whether
other downstream effectors of IFN1 signaling might be
involved in the modulation of PD-L1 expression needs further
investigations. Similarly, in mouse IL-27-treated pDC, STAT3-
dependent enhancement of PD-L1 was described (40). The
TLR-agonist-induced PD-L1 expression was modulated in a
MAPK/STAT3-dependent way, whereby STAT3 was rapidly
recruited to the PD-L1 promoter and in agreement with
our findings, blocking of STAT3 activation prevented PD-L1
expression (61). We showed previously that IL-27-induced
specific up-regulation of the PD-L1 regulatory molecule on
DC was accompanied by the phosphorylation of another
STAT family member, STAT1 protein (19), but we did not
observe STAT1 involvement in the IFNα-induced PD-L1
expression.
Furthermore, in several tumor cell types, the role of
Jaks/STATs in PD-L1 regulation was highlighted recently.
Attenuation of IFNγ-induced PD-L1 expression in melanoma
cells was proven to happen via down-regulation of the
Jak/STAT/IRF-1 signaling pathway (67, 68), while activation of
Jaks led to PD-L1 up-regulation in hematopoietic tumor cell
lines and primary tumor cells (69). In contrast to our previous
observations, neither PI3K nor ERK activation was essential
for IFNα-induced PD-L1 expression (18). Thus, our findings
underline the important roles of STATs in the regulation of PD-L1
expression and are in agreement with Barton et al. who states that
the stimulatory ability of APCs depends on the degree of STAT3
activation (70). We can also speculate that therapies that target
p38 and STAT3 pathways could potentially produce a desirable
secondary effect on PD-L1 expression.
Another type I IFN, IFNβ, is also used as an
immunomodulatory cytokine in the treatment of multiple
sclerosis (71) and in anti-cancer therapies, for example against
nasopharyngeal carcinoma (72). Since other type I IFNs bind the
same IFNR1/2 receptor complexes and have a similar mode of
action (73), one could assume that the effects found in our IFNα
study might be valid for them as well and so more attention
needs to be paid to these IFNs in future studies. Giving further
evidence to support this hypothesis, IFNβ-dependent facilitated
increase in PD-L1 expression in DC was documented in multiple
sclerosis and in immune paralysis (30, 31).
Our findings underline the important roles of p38 and STAT3
in the regulation of PD-L1 expression and showed that IFNα-
2b, which is clinically used for a wide range of indications
including cancers, induced STAT3/p38-mediated expression of
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FIGURE 6 | IFNα up-regulates PD-L1 expression in mDC in p38/STAT3-dependent manner. (A,B) FACS analysis of PD-L1 expression on mDC activated for 24 h with
1,000 U/ml IFNα with or without 1 h pre-incubation with signal transduction inhibitors of p38, STAT3 (ST3), PI3K, ERK, p38, and Jak. The results are presented as
column bar graphs and statistically analyzed using ordinary one-way ANOVA with the Dunnett’s multiple comparisons post-test, n = 8–10, *p < 0.05, **p < 0.01, and
***p < 0.001. (C) Western blot analysis of p38, STAT3, and ERK phosphorylation (pp38, pERK, and pSTAT3 for phosphorylated form) in mDC before and after
activation for indicated period of time with IFNα.
PD-L1, favoring a reduction in the stimulatory ability of DC.
Particular consideration should be given to the enhanced PD-L1
expression in multiple immune cell types caused by the use of
IFNα in anti-cancer therapy in the future.
The obtained results reveal a new avenue for the development
of novel and optimization of existing therapeutic strategies with
IFNα, in order to precisely modulate PD-L1 expression in DC
and other target cells.
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